In this paper the problem of assessing the similarity of two cumulative distribution functions (c.d.f.'s) F and G is considered. An asymptotic test based on an ?trimmed version of Mallows distance ? (F; G) between F and G is suggested, thus demonstrating the similarity of F and G within a preassigned ? (F; G)-neighbourhood at a controlled type I error rate. The proposed test is applied to the validation of goodness of t and for the nonparametric assessment of bioequivalence. It is shown that ? (F; G) allows an interpretation as average and population equivalence. Our approach is illustrated by various examples.
Introduction
One of the main goals of statistical inference is the assessment of a signi cant di erence between several populations. Rejection of the hypothesis of equality, at a controlled error rate, leads to the empirically founded knowledge of a di erence between populations. However, if the hypothesis cannot be rejected, one is left with an inconclusive answer, i.e. the conclusion of similarity cannot be drawn with any evidence. This situation arises, for example, when a goodness of t test should ensure that the observations are outcomes of a normal distribution. Usually, this de ciency is overcome by applied statisticians by choosing the level of signi cance rather large, in the hope that consequently the type II error small. Moreover, a large p-value is considered as su cient evidence for the validity of the model. The following example illustrates the above proceeding, which is sometimes denoted as the power approach. Example 1. In a multiclinical study performed at the Biometrical Centre, Department of Medical Statistics at G ottingen University, the cholesterol and brinogen levels were measured from 116 and 141 patients in two di erent clinical centres, respectively. Figure 1 displays the corresponding histograms and estimators of the densities.
Cholesterol Level
Fibrinogen Level Centre 1 K-S-stat. .095 (.012) K-S-stat. .092 (.066) Centre 2 K-S-stat. .136 (.000) K-S-stat. .161 (.000) Therefore,assuming a nonparametric linear model, a two-sample Wilcoxon-Mann-Whitney (WMW) test for the cholesterol and brinogen levels was performed, respectively. This leads to a p-value of :02 in the rst case and to :33 in the second case, i.e. we know at a controlled error rate of = :05 that there is a di erence between the clinical centres with respect to the cholesterol levels. The rather large p-value for the brinogen values indicates homogeneous distributions at both centres. In comparison, a standard two sample t-test gave a p-value of :11 for the cholesterol levels and :58 for the brinogen levels. In accordance with common practice one would omit the clinical centre as an in uential factor for the brinogen levels within a (non)parametric linear model. Following two questions arise: Firstly; how large is the minimal di erence within cholesterol levels, and secondly; how large is the evidence for the homogeneity within brinogen levels ?
The rst question arises from the unsatisfactory observation, that the pure test decision of rejecting the null hypothesis F = G alone, does not contain any information about the level of di erence (Staudte & Sheather (1990) , Victor (1987) ). Therefore, it is only of interest to show a scienti c relevant di erence in contrast to a purely statistical di erence. Although the second question cannot be answered by the power approach relatively little attention has been devoted to this problem in the statistical literature. In contrast, this problem is recently well documented in applications (cf. Rogers et. al. (1994) and MacKinnon (1994) for a discussion in Psycholgy and Econometry). From a methodological point of view this problem is directly related to bioequivalence testing which has become a challenging eld during the last two decades (Mandallaz & Mau (1981 ), Schuirmann, (1987 and Chow & Liu (1992) ). In broad terms, the 'equivalence way' is to replace the classical Null hypothesis of equality by a suitable 'neighbourhood' which becomes the alternative. As long as a (semi-) parametric model can be assumed, the hypothesis can be formulated in terms of the relevant parameters. For example, in the normal model, the most common parameter of interest is the di erence of the means . The hypothesis of nonequivalence H : j j > is chosen in order to show K : j j , where denotes a prespeci ed equivalence limit for which the treatments are considered pharmacokinetically similar. This is denoted as average bioequivalence, and represents the most popular criterion for bioequivalence (see also Brown, Casella & Hwang (1995) for the multivariate case and Giani & Stra burger (1992) for the k-sample problem). Various authors criticised this concept (Anderson & Hauck (1990 ), Holder & Hsuan (1993 ) because average bioequivalence focuses only on the comparsion of the means of the underlying distributions. Therefore, Hauck & Anderson (1992) suggested a bioequivalence criterion which requires the entire distribution of the test formulation to be su ciently similar to the reference formulation. For a patient being started on a new drug, it was concluded that this criterion, which is denoted as population equivalence, seems to be more appropriate than average bioequivalence. In practice, parametric assumptions are often not justi ed (Chow & Liu, 1992 ) and a nonparametric model therefore becomes necessary. The aim of this paper is to provide a test for the assessment of similarity of distributions within a purely nonparametric framework. In Section 4, we show that this test can be used as a nonparametric test for population as well as average equivalence. In particular, the exible chioce of trimming allows for robust bioequivalence assessment which is required in many practical situations (see Chow & Tse (1990) ). Crucial for the success of a a nonparametric equivalence test is the choice of the measure of discrepancy between probability distributions. While it is necessary that this measure should be not too complicated it is also pertinent that it contains all the relevant information to the experimenter. In this paper, we propose to use a trimmed version of the Mallows (1972) 
and its dual problem K against H will be provided in the next section. As a more precise measure of the evidence of the test decision we propose the corresponding asymptotic p-value function given a xed outcome of observations. This is illustrated in two examples in Section 4. In contrast to the test for the classical Null ?(F; G) = 0 (de Wet & Venter (1972) ) it was found that for equivalence testing additional estimation of the variance of the empirical Mallows distance is required which is numerically rather cumbersome. Therefore in Section 3 we report brie y on the nite sample behavior of the proposed tests from a comprehensive simulation study. In particular, sample size driven recommendations for the choice of trimming are given. In Section 4 we apply our test to nonparametric bioequivalence testing.
In Section 2 it is shown that the di erences in the moments of F and G up to the p-th order are close, whenever the Mallows distance is small. This guarantees bioequivalence on a moment based criteria. A numerical power comparsion with the (asymptotic optimal) standard test under normality shows the somewhat paradoxical result that Mallows equivalence is more powerful in most cases. This observation is explained by the vanishing power function of the standard test as the variance increases (Brown, Hwang & Munk,1995) . Finally, the data of Example 1 are reanalyzed and a relevant di erence of the cholesterol levels between the clinical centres as well as in the case of the brinogen levels is demonstrated. A second example illustrates the use of the p-value function for the assessment of equivalence.
The rst part of Section II is pertinent to those with an interest in applications exclusively. Chapter 3 and 4 are understandable without previous reading of the more technical part 2 of Section 2.
Asymptotic Theory of the Mallows Distance
In this section, we brie y provide the required notation and asymptotic results for inference based on the Mallows distance.
2. (Dobrushin, 1970) , Mallows (1972) , (Bickel and Freedman, 1981 (1?2 ) ?1 . In the case of h being a normal density (see also (1984) The following asymptotic result in the one sample case will be used for the validation of goodness of t in the sense of (1) where G is a speci c c.d.f.. For example, proving goodness of t to a standard normal distribution is required, if one is interested in verifying the model assumptions of a (generalized) linear model. For this, note that the studentised residuals for large samples are approximately a sample from a standard normal distribution if the model assumptions are correct (see for example Cook and Weisberg (1986) p. 56). We return to this problem in Section 4, Example 2. The next theorem provides the asymptotic theory in the two-sample case, which will be used to assess the nonparametric equivalence of two distributions. 
holds, then the distribution of (nm=(n + m)) too soon. With this argument the assumptions A1-A4 are not real restrictions for the distributions in order to guarantee the limit law, rather, they are indicators for those cases where the asymptotic convergence might deteriorate. This will be the case, when the distributions have heavy tails (A3) and when the density is strongly peaked or almost zero (A1). These observations are supported by a simulation study which will be presented in the next section.
In the case (F; G) = 0 we have (nm=(n + m)) 1=2 f? 2 n^m (F m ; G n ) ? g ! p 0 as n^m ! 1 (7) which happens in particular for F = G. This is explained by the fact, that in this case is a von Mises functional of rst order degeneracy. A nondegenerate weak limit is obtained when (7) is multiplied by
. The resulting distribution was calculated by de Wet and Venter (1972) for the case of F = G standard normal. These authors used this result to obtain a goodness of t test for testing the hypothesis H : F = . However, our aim is to provide tests for the hypotheses (1) and the converse problem where 0 > 0 is a positive bound. The following Theorem shows that the convergence in (7) is enough to prove consistency of our tests. 
is a consistent test for the di erence problem K against H. ). Observe, that this implies nm=(n + m)(? (F m ; G n )) 2 < 1 a.s.. In other words, we are still able to assess asymptotically with probability 1 the similarity of F and G as long as the sequence of hypotheses H n;m approaches K : = 0 with slower rate as n ?1=2 . (F m ; G n ) as a Riemannian sum. In the untrimmed case ( = 0) this simpli es to
for equal sample sizes and to For the rst three simulation studies F (G) was assumed as standard normal (normal with mean and standard error ) and a sample of size m (n) was drawn from F (G). Values for ranged between .1 and 2.6 and for between .5 and 1.5. In the rst study, we investigated large equal sample sizes (n = m = 50; 100; 200), while in the second study we focused on small equal sample sizes (n = m = 10; 15; 20; 25). For the third study, nonequal sample sizes have been studied (n = 100 and m = 30; 50; 75; 90). For large (small) samples trimming constants of = :05 and .1 (0,.1) were investigated. 500 (250) data sets from each parameter setting were generated for the rst two (third) Czado (1992) ) with heavier right tail ( < 1) and lighter right tail ( < 1) than the logistic distribution ( = 1). For >> 1, the corresponding density is highly peaked. Here, n = 25; 50 and 100 with m n = :96 and :48 were investigated. It was observed, that in the heavy tail case ( < 1) the nominal size was better maintained for a 16 % trimming than a 8% trimming. However, the observed power is adequate for n 25. In contrast, for the highly peaked case ( > 1), the nominal size was maintained for both trimmings, but the observed power was inadequate for n = 25; 50. Therefore, the conclusions in Remark 2.1 were exactly supported.
To summarise, the e ect of heavy tailed and strongly peaked densities decrease the quality of the approximation. It was found that as in the normal case the bound o = 1 serves as a change point for the quality of the asymptotic normal approximation to the nite sample distribution.
Applications and Examples
4.1 Nonparametric bioequivalence testing. In bioequivalence studies, when normality of the data is assumed, the two one sided test procedure should be applied in a 2 2 crossover desgin as recommended by various regulatory authorities (FDA, 1992) , (EC-GCP,1993) . If this distributional assumption fails a distribution-free rank sum test was suggested by various authors as a nonparametric alternative (see Hauschke, et. al. (1990 ), or Hsu et. al. (1994 ). This test, however, should be applied only when a pure location di erence between test and reference formulation can be assumed because otherwise the test decision may be extremely misleading. Therefore, as mentioned in the introduction, it is important to compare the entire distributions which should include speci cally the between-subject variability of bioavailability (see Chow & Liu (1992) , pp. 186, 218) in order to guarantee exchangeability in the test formulations. When an equivalence test is based on two independent samples Lemma 2.2 and 2.3 guarantee that these requirements are exactly ful lled by the Mallows distance ? (F; G) because the rst two trimmed moments are close whenever ? is small. Hence, the proposed test applies for population and average equivalence, simultaneously. If one, in addition, wants to control higher moments , p can be suitably chosen. However, for nonparametric bioequivalence testing, the case p = 2 should be su cient for most applications (Holder & Hsuan, 1993) . One might argue that Mallows test cannot be applied to both periods in a two (or more) period cross-over design, as it is standard when carry-over e ects can be excluded. This is not caused, however, by the particular choice of the measure of equivalence ? (F; G). Merely that, no nonparametric measure allows for a proper analysis in a crossover design because the interpretation of the test decision can be distorted heavily by the dependence structure of the observations. Only, whithin a semiparametric linear model when the parameter of interest is a shift (as required by the WMW-test) a cross-over design remains tractable. Another common problem encountered with decision making in bioequivalence studies consists of the detection of outlying observations because these have dramatic e ects on the bioequivalence tests (Chow & Tse (1990) and Liu & Weng (1991) ). Therefore, a trimmed version of Mallows statistic may be especially useful to the applied working statistician. In this case, we nd from the discussion in Section 2, that testing bioequivalence by using the trimmed Mallows statistic is tantamount to the assessment of similar trimmed moments and distributions, simultaneously. A key issue in the nonparametric bioequivalence discussion is the required sample size in order to control a small probability of type II error. Therefore Czado & Munk (1996) simulated the relative e ciency of the Mallows equivalence test and the standard equivalence test under a linear model with additive normal errors. Typically, such a model occurs after a logarithmic transformation of the raw data (as the area under the blood concentration-time curve or the time to achieve maximal concentration) where the ratio of the means has to be within some reasonable limits. When we assume a multiplicative linear model the parameter of interest is the absolute di erence of the means j T ? R j, where T ; R denotes the mean of the test and reference drug, respectively (Mandallaz & Mau, 1981) . Observe, that the trimmed Mallows distance reduces after rescaling exactly to this quantity, i.e.
1=2
(1 ? 2 ) 1=2 = j T ? R j:
Suprisingly, the simulation study shows that the power of the standard test was in most cases slightly exceeded by the Mallows test, although the standard test can be shown to be asymptotically optimal.
This curious nding can be explained by the fact that only when the unknown variance 2 is rather small compared to the equivalence bound 0 the asymptotic optimality allows for a valid interpretation in realisitc sample sizes, say, m; n 20. Otherwise, the power tends uniformly to 0 as pointed out by Brown, Hwang & Munk (1995) . In addition, Mallows test was found always to be liberal which causes an additional power improvement. It is interesting to note that trimming does not a ect the nite sample approximation under the standard model because variance homogeneity in both groups is assumed. Therefore, Mallows test represents a valid and powerful tool in bioequivalence assessment to guard against outliers.
4.2 p-value curves associated with Mallows test. In order to get a more precise insight to the evidence against the test decisions in (8) and (9), the additional consideration of the asymptotic p-value function corresponding to the hypothesis H and K in (1) is helpful. In the one sample case X F and G xed, this asymptotic p-value function is given by P( 0 ) = lim n!1 sup
if the sample X = x is observed. Here T(X) denotes the Mallows test statistic n 1=2 (? 2 n (F n ; G) ? 2 0 )= (F n ; G) and t the corresponding observed statistics at X = x. The two sample case is similar. The function P( 0 ) can be interpreted as follows. If P( 0 ) , the data leads to the rejection of the hypothesis of nonequivalence H : ?(F; G) 0 at level , whereas by reasons of symmetry, we reject the hypothesis of equivalence H : ?(F; G) 0 whenever P( 0 ) 1? . For a careful discussion of the use of p-values corresponding to precise interval hypotheses as a measure of evidence in the parametric case, see Berger & Delampady (1987) and the subsequent discussion. Although these authors gave strong reasons against a naive use of p-values, we agree with Cox's rejoinder (pp.335). Sometimes a substantial improvement on p-values may be possible, however, the conclusion that p-values have no role, is incorrect. In particular, (10) shows that P( ) equals asymptotically the p-value function of a one sided test. Pratt (1965) showed that this allows for a valid Bayesian interpretation in a parametric setup as a measure of evidence for H.
Example 1 (continuation). Recall that a two-sample WMW test detected a signi cant di erence between the two centres with regard to the cholesterol levels (p-value=.02) but not for the brinogen levels (p-value=.33). In addition, there was evidence that the samples from each centre and group do not come from a normal population. Alternatively, the nonparametric tests given in Section 2 were applied to this problem. Figure 4 gives the corresponding p-value curves for 1.4%, 4.3% and 10% trimming for brinogen and cholesterol levels, respectively. >From the curves for 1.4% trimming, we see that an absolute di erence of 15 and of 8 at level = 0:1 are present for the brinogen and cholesterol levels, respectively. When we standardise these values, this corresponds to about 5% and 2% of the medians of the brinogen and cholesterol levels, respectively. For the brinogen levels, this signi cantly contradicts the nding of the Wilcoxon-Mann-Whitney test, which can be explained by the fact that this test focuses only on R FdG as a measure of discrepancy and not on the entire distributions. >From theses curves it is further concluded, that the cholesterol levels between the two centres are equivalent, if one tolerates a di erence 0 = 42 which corresponds to about 12% of the medians for the two samples. One can show a similar equivalence for the brinogen levels if at least a 4:3% trimming is allowed. For 1:4% trimming equivalence with regard to 15% of the medians can still be shown. This indicates the presence of outliers in the data, which is also evident from Figure 1 . To summarize, the last example illustrates a systematic error whenever assessing equality of distributions by means of accepting the null hypothesis (power approach). Although we could show similar situations by Mallows equivalence test for the cholesterol and the brinogen levels it is found to be di erent when using the WMW test, because the underlying test criterion focuses on a misleading measure of discrepancy R FdG, and, hence, is unable to detect a signi cant di erence in one situation, although it is equally evident to the other situation. The next example illustrates the opposite e ect. The K-S-test behaves too sensitively and detects a di erence which is not larger than in a situation where no di erence is indicated.
Example 2. Steinho , Fangmeier and Paulus (1995) investigated the in uence of epilepsy on extroceptive suppression of temporalis (es1) and masseter (es2) muscle activity. They compared the extroceptive suppression of muscle activity of 31 epileptic patients and 20 normal controls. Measurements were taken from each subject at the left and right temporalis and masseter, respectively. Further, measurements for each subject have been averaged to form the variables; es1 and es2. The results of an explanatory analysis are given in Table 2 This indicates that only the es2 values for patients show evidence of non normality. In order to investigate goodness of t to a normal distribution we standardise the data and use the one sample Mallows equivalence test. Note that this involves the estimation of the mean and variance by its sample estimators. The asymptotic results of Section 2 are therefore not immediately applicable, and extensions of results for proving composite normality are currently considered. However, for illustration, the corresponding one sample p-value curves are plotted in Figure 5 for the two variables of the patient group. It shows equivalence at 0 = :4 and 0 = :5 for the standardised es1 and es2 values, respectively. This corresponds to :4 3:67 1:5 and :5 11:71 5:9 on the original scale and therefore to 8% and 13% of the means for es1 and es2, respectively. If one allows for 19.4% trimming for the es2 data, only then a signi cant di erence of .1 on the standardized scale can be detected. A closer look at the data shows a cluster of 3 observations in the far right tail. Removing these shows a more non-normal histogram, explaining the last nding. To summarize, the one sample nonparametric equivalence test agrees with the K-S-test for composite normality for the variable es1. For es2 variable, however, there is not much more evidence to assume nonnormality (as falsely the K-S test indicates). >From the p-value curves of Mallows statistic the precise amount of what we want to denote as similar can be drawn.
Hence, our subsequent data analysis can be adapted accordingly. Finally, the p-value curves for the two sample nonparametric equivalence test are given in Figure 6 for the normal subjects and patients, respectively. They prove similarity of es1 values for the normal subjects and patients up to 0 = 1:2 which corresponds to 100 1:2=19:5% 6% of the mean. The similarity of the es2 values for the two groups only occurs at 0 = 6:2 which corresponds to 100 6:2=42:94% 15%. Ultimately, the clinician must decide whether these values should be regarded as empirical evidence for the similarity or for a scienti cally relevant di erence of the underlying distributions.
Conclusions and Discussions
It has been illustrated by two examples, that the assessment of similarity of two distributions from accepting the hypothesis of equality may lead to wrong decision with high probability, even when large p-values are observed. But even when we reject the null hypothesis of equality, the pure test decision gives no information about a scienti c relevant di erence between the distributions. To overcome these di culties, a nonparametric measure of discrepancy between two distributions which generalizes the Mallows distance is proposed. Based on this measure, tests for precise interval hypotheses are provided. Moreover, the associated p-value function represents a very informative tool for the exact level of similarity as well as for a relevant di erence. We conclude, that when testing goodness of t, the classical power approach to`prove the null hypothesis' by accepting equality at a rather large level is insu cient and should be additionally supported by a consideration of the Mallows p-value function. Our approach applies also to the nonparametric assessment of bioequivalence because the proposed measure of discrepancy has an immediate interpretation of the direct drug e ect in terms of average as well as population bioequivalence. In addition to the between-subject variability similarity of the entire distributions can be tested in contrast to the commonly applied WilcoxonMann-Whitney test. Nevertheless, one problem occurs which is not known from testing the classical Null hypothesis of equality. In most applications the main di culty will consist in the determination of precise bounds for which the distributions are regarded as similar or scienti cally di erent. Assuming n = m and = a n , T 1 (F n ; G n ) can be calculated using (11) and substituting empirical cdf's F n and G n for F and G, respectively, as: T 1 (F n ; G n ) = The expression for T 3 (F n ; G n )(T 4 (F n ; G n )) is the same as T 1 (F n ; G n )(T 2 (F n ; G n )) except the role of x (i) and y (i) is reversed. In the case of unequal sample sizes, boundary terms have to be included, in particular for m n, T 
where the second summand (14) asymptotically vanishes of order o p ((nm=(n + m)) ?1=2 ) which is a direct consequence of the C-S-inequality. Now we apply Theorem 2.4 and we obtain nm n + m 
The dual testing problem is treated similarly. 
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Figure 6: Two sample p-value curves for es1 and es2 data.
